Working... Menu

Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03222752
Recruitment Status : Recruiting
First Posted : July 19, 2017
Last Update Posted : August 1, 2017
Information provided by (Responsible Party):
Electromedical Products International, Inc.

Brief Summary:
Efficacy of Cranial Electrotherapy Stimulation (CES) for the treatment of Major Depressive Disorder

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Device: Cranial Electrotherapy Stimulation Device: Sham Cranial Electrotherapy Stimulation Not Applicable

Detailed Description:
A 6 week, randomized, double-blind, placebo controlled trial of the efficacy and tolerability of Cranial Electrotherapy Stimulation for the treatment of Major Depressive Disorder, with a 2 week open label extension phase. This study will take place in Puerto Rico.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 141 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A single site, 6 week, randomized, double-blind, placebo controlled evaluation of efficacy and tolerability of cranial electrotherapy stimulation (CES) for the treatment of adults from 18-65 years of age with treatment resistant Major Depressive Disorder (MDD) with a 2 week open label extension phase.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Treatment device will deliver subsensory treatment while the sham device will deliver no treatment.
Primary Purpose: Treatment
Official Title: A 6 Week, Randomized, Double-blind, Placebo Controlled Trial of the Efficacy and Tolerability of Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder, With a 2 Week Open Label Extension Phase.
Actual Study Start Date : June 5, 2017
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Treatment Group
Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
Device: Cranial Electrotherapy Stimulation
Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
Other Name: Alpha-Stim

Sham Comparator: Sham Treatment Group
Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
Device: Sham Cranial Electrotherapy Stimulation
The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
Other Name: Sham Alpha-Stim

Primary Outcome Measures :
  1. Hamilton Depression Scale [ Time Frame: 6 weeks ]
    The Hamilton Rating Scale for Depression (HRSD), also called the Hamilton Depression Rating Scale (HDRS), abbreviated HAM-D, is a multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.

Secondary Outcome Measures :
  1. Clinical Global Impression - Severity of Illness [ Time Frame: 6 weeks ]
    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.

  2. Clinical Global Impression - Global Improvement [ Time Frame: 6 weeks ]
    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Patients must be able to provide informed consent and sign the informed consent form prior to the conduct of any study specific procedures. To be eligible to participate in the study, patients must meet the following criteria:

  1. Subject is a male or female outpatient age 18 (21 in Puerto Rico) to 65 years, inclusive.
  2. Subject meets DSM-5 criteria for MDD as determined by MINI screening interview.
  3. The subject has a score of > 4 on CGI-S on visit 1 and 2.
  4. Sexually active female patients of childbearing potential must be practicing at least one or more the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception or abstinence. Female patients of childbearing potential must have a negative pregnancy test prior to receiving study treatment.
  5. Subject is in good medical health or with chronic medical conditions which are currently stable.
  6. No current abuse of alcohol or other substance.
  7. Capable of doing active or sham CES treatments and completing all study requirements independently.
  8. The subject has a score of ≥ 17 on the HAM-D. If a subject is being treated with Serotonin Selective Reuptake Inhibitor (SSRIs) medications which include: Fluoxetine (Prozac), Paroxetine (Paxil), Sertraline (Zoloft), Luvox (Fluvoxamine), Citalopram (Celexa) and Escitalopram (Lexapro), as well as serotonin and norepinephrine reuptake inhibitors (SNRI) such as Venlafaxine (Effexor IR and XR), Desvenlafaxine (Pristiq) and Duloxetine (Cymbalta) they may remain on one of the SSRI or SNRI medications provided that he or she has been on a stable dose for at least 4 weeks prior to entering this study; this dose is to remain stable throughout the remainder of this study (any need to change the dose during the study will be evaluated and will result in termination).

Exclusion Criteria:

Patients will be not be considered for inclusion into the study if they meet any of the conditions below:

  1. Subject meets DSM-5 criteria for another axis 1 disorder (other than MDD) as the primary diagnosis (i.e., schizophrenia, mood disorder, psychosis, anorexia nervosa) as determined by the MINI. Conduct and antisocial personality disorders will not be allowed to participate. Patients with comorbid diagnoses of learning disorders, attention deficit disorder (with or without hyperactivity), communication disorders, separation anxiety disorder, dysthymic disorder or anxiety disorders will be allowed to participate in the study as long as these conditions are not the primary focus of any treatment and they comply with concomitant medication limitations listed in the appendix. Those with substance use disorders will not be allowed to participate.
  2. Subject is clinically judged by the investigator to be at risk for suicide or is acutely suicidal as objectively measured by the C-SSRS.
  3. Subject has attempted suicide one or more times within the past 12 months
  4. Subject has a Hamilton Depression Rating Scale17 (HAM-D17) score above 38 which suggests a moderate to severe clinical level of depressive symptoms
  5. Subject has a psychiatric condition that would require inpatient, or partial psychiatric hospitalization.
  6. There is an imminent risk of injuring self or others or causing damage to property as judged by the investigator.
  7. Subject has a significant history of medical disease (i.e., cardiovascular, hepatic (e.g., cirrhosis, hepatitis B or C) renal, gynecological, musculoskeletal, neurological, gastrointestinal, metabolic, hematological, endocrine, cancer with a metastatic potential, progressive neurological disorders or seizure disorder) which could impair reliable participation in the trial or necessitate the use of medication not allowed by this protocol unless all of the following are true (consultation with study physician is encouraged before patient enrollment):

    1. The condition has been stable for over one year (3 years for malignancy other than excised basal cell carcinoma, for which one year stability is required).
    2. The condition has been judged by the Investigator not to interfere with the patient's participation in the study.
    3. The condition is fully documented in the patient's study records.
  8. Hypo- or hyperthyroidism, unless stabilized on appropriate pharmacotherapy with no change in dosage for at least three months before visit 1 (Screening).
  9. Subject is pregnant, planning to become pregnant, or nursing. If a subject becomes pregnant, she will be discontinued immediately and followed appropriately.
  10. For females who are sexually active:

    Not practicing a reliable method of contraception that will continue for the duration of the study and within 30 days following the end of study participation.

    Reliable contraception is defined as:

    1. surgical sterilization
    2. oral contraceptives (consisting of an estrogen-progestin combination or progestin alone
    3. transdermally derived contraceptives (e.g., Ortho - Evra), depot injections (e.g., Depo-Provera)
    4. vagina contraceptive ring (e.g., Nucaring), contraceptive implants (e.g., Implanon, Norplant 2/Jadelle)
    5. an intrauterine device
    6. diaphragm plus condom (the only acceptable double barrier method)
    7. other forms of contraceptives (pharmacological and/or non-pharmacological) are not accepted
  11. Subject has had concomitant therapy with another investigational drug, or participation in an investigational drug study within one month prior to entering this study.
  12. Subject who has initiated or terminated psychotherapy or behavior therapy within one month before visit 1 (screening), or who plans to initiate or change such therapy during the course of the study.
  13. Subject has history of poor compliance or in the Investigator's opinion any subject whose treatment as an outpatient would be clinically contraindicated.
  14. Subject has had previous trial of cranial electrotherapy stimulation (CES).
  15. Subject requiring prohibited concomitant medication or herbal supplements that could not be discontinued or switched to an allowable alternative medication and stabilized for at least two weeks preceding (visit 2).
  16. Subject taking any psychoactive drug or herbal remedy within 5 half-lives before baseline (visit 2), (St. John's wort, ginkgo biloba, kava kava, valerian root, DHEA, tyrosine, tryptophan and 5-HTP, antidepressants, anxiolytics, monoamine oxidase inhibitors, antipsychotics, or anticonvulsants/mood stabilizers, carbamazepine, or others). Patients who have ever been treated with the depot antipsychotic must also be excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03222752

Layout table for location contacts
Contact: Michel Woodbury-Farina, MD 787-754-0872

Layout table for location information
United States, Texas
Electromedical Products Recruiting
Mineral Wells, Texas, United States, 76067
Contact: Jeff A Marksberry, MD    940-328-0788   
Sponsors and Collaborators
Electromedical Products International, Inc.
Layout table for investigator information
Principal Investigator: Michel Woodbury-Farina, MD Univeristy of Puerto Rico

Layout table for additonal information
Responsible Party: Electromedical Products International, Inc. Identifier: NCT03222752     History of Changes
Other Study ID Numbers: MDD1
First Posted: July 19, 2017    Key Record Dates
Last Update Posted: August 1, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: PI will maintain all patient data during the trial. Data will be de identified and encrypted before sending to the designated statistician.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Electromedical Products International, Inc.:
Cranial Electrotherapy Stimulation

Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms